René Gerolami

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.6K citations · Full text

Hepatology, Medicine, Sorafenib Treatment +8

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 794 citations

Hepatology, Radiation Therapy, Hepatocellular Carcinoma +10

Pig Liver Sausage as a Source of Hepatitis E Virus Transmission to Humans

Philippe Colson, Patrick Borentain, Benjamin Queyriaux et al. · The Journal of Infectious Diseases · 2010 · 648 citations

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Richard S. Finn, Philippe Merle, Alessandro Granito et al. · Journal of Hepatology · 2018 · 350 citations

Additional Analyses, Oncology, Medicine +6

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Masatoshi Kudo, Zhenggang Ren, Yabing Guo et al. · The Lancet · 2025 · 161 citations

Hepatology, Non-metastatic Hepatocellular Carcinoma, Transarterial Chemoembolisation +8